Gefitinib


Gefitinibb Treatment
Side Effects Research and Resources

Research and Resources about Gefitinib

Resources

Medline

Cancer growth blockers (tyrosine kinase inhibitors and proteasome inhibitors)

Registered clinical trials on gefitnib
http://clinicaltrials.gov/ct2/results?term=gefitnib

Prescribing Information for gefitnib
http://www1.astrazeneca-us.com/pi/iressa.pdf

FDA Postmarketing Information on gefitnib
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085197.htm

More FDA postmarketing info

National Cancer Institute

 

Research

Glenmark cuts prices of lung cancer drug by up to 70%

An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902

Attenuated expression of a novel mitochondrial and metabolic gene contributes to acquired gefitinib resistance in lung tumors

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation

Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer

Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Multiple Myeloma Emerging after Prolonged Gefitinib Treatment for Non-Small Cell Lung Carcinoma

Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.

The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis

Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

 

 

Gefitinibb Treatment
Side Effects Research and Resources

About This Website